KNTE Live signals | Maximize Profits with Getagraph.com

BUY 96121 min ago

@ $2.26

Issued: 12 Feb 2024 @ 09:31

Return: 17.26%

Previous signal: Feb 9 - 12:11

Previous signal: Sell

Return: -2.59 %

Live Chart Being Loaded With Signals

Commentary (2 Apr 2024 @ 16:00):

Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States...

Stats
Today's Volume	2.12M
Average Volume	417 575
Market Cap	124.99M
EPS	$-0.362 ( 2024-04-03 )
Next earnings date	( $-0.360 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.950
ATR14	$0.00300 (0.11%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-03	Tananbaum James B.	Sell	520 711	Common Stock
2024-04-03	Tananbaum James B.	Sell	40 501	Stock Option (right to buy)
2024-04-03	Tananbaum James B.	Sell	20 250	Stock Option (right to buy)
2024-04-03	Farzan Nima	Sell	2 186	Common Stock
2024-04-03	Farzan Nima	Sell	1 281 642	Stock Option (right to buy)

INSIDER POWER
-20.87
Last 99 transactions
Buy: 9 508 542 \| Sell: 7 832 534

Volume Correlation

Long: 0.00 (neutral)

Short: -0.05 (neutral)

Signal:(69.591) Neutral

Kinnate Biopharma Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Kinnate Biopharma Inc. Correlation - Currency/Commodity

-0.44
( neutral )

0.02
( neutral )

0.00
( neutral )

0.40
( neutral )

Kinnate Biopharma Inc. Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-799 000 (0.00 %)
EPS:	$-2.42

Q4	2023
Revenue:	$0
Gross Profit:	$-198 000 (0.00 %)
EPS:	$-0.360

Q3	2023
Revenue:	$0
Gross Profit:	$-197 000 (0.00 %)
EPS:	$-0.650

Q2	2023
Revenue:	$0
Gross Profit:	$-201 000 (0.00 %)
EPS:	$-0.680

Financial Reports:

No articles found.

Kinnate Biopharma Inc.

Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.